{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:33:25Z","timestamp":1783532005343,"version":"3.55.0"},"reference-count":87,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00287","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T04:53:56Z","timestamp":1512968036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle"],"prefix":"10.3389","volume":"7","author":[{"given":"Ehsan","family":"Malek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"El-Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1701980","article-title":"Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation","volume":"24","author":"Libura","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1182\/blood-2012-04-420802","article-title":"Death of frontline allo-SCT in myeloma","volume":"119","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1182\/blood-2008-12-173526","article-title":"Reduced-intensity allogeneic transplantation for myeloma: reality bites","volume":"113","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/bmt.2014.237","article-title":"Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents","volume":"50","author":"Jimenez-Zepeda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"De Larrea","year":"2013","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/bmt.2013.37","article-title":"Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma","volume":"48","author":"Nishihori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous\u2013allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kr\u00f6ger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","first-page":"43","article-title":"Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma","volume":"124","author":"Knop","year":"2014","journal-title":"Am Soc Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2009.07984.x","article-title":"Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation","volume":"148","author":"Kr\u00f6ger","year":"2010","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bbmt.2015.02.015","article-title":"Cord blood transplantation for multiple myeloma: a study from the multiple myeloma working group of the Japan society for hematopoietic cell transplantation","volume":"21","author":"Kawamura","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3324\/haematol.2015.138917","article-title":"Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the cord blood committee of cellular therapy and immunobiology working party, and the chronic leukemia working party of the European Society for Blood and Marrow Transplantation","volume":"101","author":"Paviglianiti","year":"2016","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide Graft-versus-host disease prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1182\/blood.V124.21.5918.5918","article-title":"Haploidentical allogeneic transplantation as salvage in relapsed multiple myeloma","volume":"124","author":"McKiernan","year":"2014","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00277-009-0696-8","article-title":"Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma","volume":"88","author":"Ayuk","year":"2009","journal-title":"Ann Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3324\/haematol.12665","article-title":"Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation","volume":"93","author":"Ayuk","year":"2008","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bbmt.2015.08.025","article-title":"CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma","volume":"22","author":"Smith","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kr\u00f6ger","year":"2005","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/leu.2011.138","article-title":"Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"25","author":"Kroger","year":"2011","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1200\/JCO.2003.04.033","article-title":"Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM","volume":"21","author":"Lokhorst","year":"2003","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/bmt.2012.1","article-title":"Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center","volume":"47","author":"Bensinger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/bmt.2013.73","article-title":"Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation","volume":"48","author":"Auner","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","article-title":"Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect","volume":"32","author":"Alyea","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bmt.2012.173","article-title":"Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment","volume":"48","author":"Armeson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2005-05-1820","article-title":"NF-\u03baB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145","volume":"107","author":"Vodanovic-Jankovic","year":"2006","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1600-6143.2008.02533.x","article-title":"Ex vivo inhibition of NF-\u03baB signaling in alloreactive T-cells prevents graft-versus-host disease","volume":"9","author":"O\u2019shaughnessy","year":"2009","journal-title":"Am J Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","article-title":"Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors","volume":"114","author":"Koreth","year":"2009","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","author":"Goldschmidt","year":"2017","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"B60","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.exphem.2012.02.009","article-title":"Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma","volume":"40","author":"El-Cheikh","year":"2012","journal-title":"Exp Hematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kr\u00f6ger","year":"2009","journal-title":"Exp Hematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1083-8791(03)00077-6","article-title":"Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation","volume":"9","author":"Dey","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1083-8791(00)70014-0","article-title":"Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma","volume":"6","author":"Orsini","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1182\/blood.V99.12.4610","article-title":"Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma","volume":"99","author":"Bellucci","year":"2002","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bbmt.2012.10.032","article-title":"Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation","volume":"19","author":"Montefusco","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease and high risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-012-1376-4","article-title":"MAGE-C1\/CT7 and MAGE-C2\/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy","volume":"62","author":"de Carvalho","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2012-06-435040","article-title":"WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions","volume":"121","author":"Tyler","year":"2013","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrclinonc.2014.177","article-title":"Immune-based therapies for childhood cancer","volume":"11","author":"Mackall","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2014","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"B85","first-page":"37","article-title":"Immunotherapy with chimeric antigen receptors for multiple myeloma","volume":"17","author":"Garfall","year":"2014","journal-title":"Discov Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/asheducation-2016.1.521","article-title":"Cellular and vaccine immunotherapy for multiple myeloma","volume":"2016","author":"Garfall","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B87","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc1512760","article-title":"Chimeric antigen receptor T cells in myeloma","volume":"374","author":"Garfall","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:38:17Z","timestamp":1660106297000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":87,"alternative-id":["10.3389\/fonc.2017.00287"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00287","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]},"article-number":"287"}}